Usefulness of the ratio free/total prostate-specific antigen in addition to total PSA levels in prostate cancer screening

Urology

Volumn 48, Issue 6 SUPPL., 1996, Pages 62-66

  Reissigl, Andreas ^a   Klocker, Helmut ^a   Pointner, Josef ^a   Fink, Klaus ^a   Horninger, Wolfgang ^a   Ennemoser, Othmar ^a   Strasser, Hannes ^a   Colleselli, Karl ^a   Höltl, Lorenz ^a   Bartsch, Georg ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER SCREENING; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY;

AGED; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; ROC CURVE;

EID: 17144466104     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(96)00612-7     Document Type: Article

References (20)

1. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, Petros JA, and Andriole GL: Measurement of prostate specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324: 1156-1161, 1991.
2. Labrie F, Dupont A, Suburu R, Cusan L, Tremblay M, Gomez JL, and Edmond I: Serum prostate specific antigen as a pre-screening test for prostate cancer. J Urol 147: 846-852, 1992.
3. Brawer MK, Chetner MP, Beatie I, Buchner DM, Vesella RL, and Lange PH: Screening for prostate carcinoma with prostate specific antigen. J Urol, part 2, 147: 846-852, 1992.
4. Catalona WJ, Smith DS, Ratliff TL, and Basler IW: Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 270: 948-954, 1993.
5. Reissigl A, Pointner J, Horninger W, Ennemoser O, Strasser H, Klocker H, and Bartsch G.: Comparison of different prostate specific antigen cutpoints for early detection of prostate cancer: results of a large screening study. Urology 46: 662-665, 1995.
6. Lilja H, Christensson A, Dahlen W, Matikainen MT, Nilsson I, Petersson K, and Lövgren T: Prostate-specific antigen in serum occurs predominantly in complex with α-1-antichymotrypsin. Clin Chem 37: 1618-1625, 1991.
7. 1 antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostate cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 51: 222-226, 1991.
8. 1-antichymotrypsin. Clin Chem 39: 2098-2103, 1993.
9. 1-antichymotrypsin as an indicator of prostate cancer. J Urol 150: 100-105, 1993.
10. Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL, and Nadler RB: Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 274: 1214-1220, 1995.
11. Oesterling JE, Jacobsen SJ, Klee GG, Petersson K, Piironen T, Abrahamsson PA, Stenman U-H, Dowell B, Lövgren T, and Lilja H: Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. J Urol 154: 1090-1095, 1995.
12. Chen Y-T, Luderer AA, Thiel RP, Carlson G, Cuny CL, and Soriano TF: Using proportions of free to total prostate-specific antigen, age, and total prostate-specific antigen to predict the probability of prostate cancer. Urology 47: 518-524, 1996.
13. Froschermaier SE, Pilarsky CP, and Wirth MP: Clinical significance of the determination of noncomplexed prostate-specific antigen as a marker for prostate carcinoma. Urology 47: 525-528, 1996.
14. Reissigl A, Klocker H, Pointner J, Ennemoser O, Falk M, and Bartsch G: Improvement of prostate cancer screening by determination of the ratio free/total prostate-specific antigen in addition to prostate specific antigen levels. Prostate, in press.
15. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, and Lieber MM: Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 270: 860-864, 1993.
16. Reissigl A, Pointner J, Strasser H, Ennemoser O, Klocker H, and Bartsch G: Frequency and clinical significance of transition zone cancer in prostate cancer screening. Prostate, in press.
17. Murphy GP, Holmes EH, Boynton AL, Kenny GM, Ostenson RC, Erickson SJ, and Barren RJ: A comparison of prostate-specific antigen, prostate specific membrane antigen, and LNCaP based enzyme-linked immonosorbent assays in prostatic cancer patients and patients with benign prostatic enlargement. Prostate 26: 164-168, 1995.
18. Oesterling JE: Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 145: 907-923, 1991.
19. Kuriyama M, Wang MC, Papsidero LD, Killian CS, Shimano T, Valenzela L, Nishiura T, Murphy GP, and Chu TM: Quantification of prostate-specific antigen in serum by sensitive enzyme immunoassay. Cancer Res 40: 4658, 1980.
20. Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse MG, and Ratliff TL: Increased specificity of prostate-specific antigen in serum. J Urol 153(suppl): 312A, 1995